Astera Labs Sees Scorpio X-Series Exiting Year Above $1B Revenue Run Rate

What happened

At a BMO event, Astera Labs SVP of Finance Nick Aberle stated that the Scorpio X-Series is on track to exit 2026 above a $1 billion annualized revenue run-rate, positioning the company to outgrow underlying AI infrastructure demand as it expands product content per system. This commentary aligns with recent guidance where Scorpio was expected to become the largest product family earlier than previously anticipated, driving Q3 2026 revenue guidance of $540-560 million. However, the company's latest 10-Q and 8-K filings show that this ramp is accompanied by gross margin compression, with Q3 gross margin guided to about 72%, down from 76.3% in Q1 2026, due to higher hardware-module and Scorpio mix. Additionally, customer concentration remains extreme, with four customers accounting for 13-29% each of Q2 revenue and one end customer exceeding 70% in 2025, making the growth outlook highly dependent on a few hyperscalers. Thus, while the Scorpio run-rate statement is a positive datapoint, it largely reiterates existing plans and does not resolve the key risks of margin erosion and customer concentration that underpin the current WAIT rating at $361.70.

Implication

The projected Scorpio run-rate above $1B by year-end suggests that revenue growth will remain strong into 2027, supporting the bull case if the company can broaden its customer base. However, the accompanying gross margin decline to ~72% highlights that the incremental revenue is less profitable, which could pressure earnings multiples if the mix shift continues. The extreme customer concentration means that any delay or re-architecture by a top hyperscaler could cause a sharp revenue shortfall, so the stock's high valuation of 166x earnings leaves little room for error. Management's forward-looking statements at investor events should be treated with skepticism, as they often present the most optimistic scenario without full disclosure of underlying risks. Therefore, maintaining a WAIT rating with an attractive entry near $300 and reassessment after Q3 results and 2027 guidance is prudent; only clear evidence of margin stabilization and diversification would justify a more bullish stance.

Thesis delta

The new commentary does not alter the core thesis but adds marginal confidence to the near-term Scorpio revenue trajectory. The company's ability to exit 2026 above a $1B run-rate for the X-Series is consistent with prior guidance, but it does not address the gross margin dilution or customer concentration concerns. As a result, the WAIT rating and $340 base-case implied value remain intact, with no change to the attractive entry level of $300.